PD-L1 as a biomarker of response to immune-checkpoint inhibitors

Antitumour immunity regulated by aberrant ERBB family signalling

Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma